YO |
ABC-TC5570 |
AcceGen |
1 vial |
Ask for price |
Description: The full designation of this line is YB2/3.0Ag30. YO was derived from a hybrid myeloma YB2/3HL by cloning in soft agar to select a non-secreting sub-population. The cells are azaguanine resistant and do not secrete IgG. |
Human IgG antibody Laboratories manufactures the high protein yo reagents distributed by Genprice. The High Protein Yo reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Yo Proteins. Other High products are available in stock. Specificity: High Category: Protein Group: Yo
Yo information
Mouse High Mobility Group Protein 20B (HMG20B) Protein |
20-abx650466 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2397.60
-
EUR 927.60
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human High Density Lipoprotein (HDL) Protein |
abx670055-10mg |
Abbexa |
10 mg |
EUR 594 |
|
Cas9 Null Mutant Protein (High Concentration) |
K140 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
Proteinase K (high conc.) |
RP02503 |
Abclonal |
100mg |
Ask for price |
|
Proteinase K (High Conc.) |
E40KMP1793 |
EnoGene |
20ug |
EUR 495 |
Cas9 Nuclease NLS Protein (High Concentration) |
K130 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 80 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
Cas9 Nickase D10A Protein (High Concentration) |
K132 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To counteract off-target mutagenic effects of this system, the Cas9 Nickase D10A was developed with a D10A mutation in its RuvC1 nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
Cas9 Nickase H840A Protein (High Concentration) |
K136 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To improve the off-target mutagenic effects of this system, the Cas9 Nickase H840A Protein was developed with a H840A mutation in its HNH-like nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
saCas9 Null Mutant Protein (High Concentration) |
K146 |
ABM |
32.5 µg (250pmol) Volume: 25µL |
EUR 155 |
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The saCas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type saCas9. Such a saCas9 protein retains its ability to bind to genomic DNA through sgRNA:genomic DNA base pairing, however, the saCas9 Null Mutant does not induce cleavage. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). |
Rat High Mobility Group Box Protein 2 (HMGB2) Protein |
20-abx652187 |
Abbexa |
-
EUR 710.40
-
EUR 309.60
-
EUR 2131.20
-
EUR 844.80
-
EUR 526.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat High Mobility Group Box Protein 4 (HMGB4) Protein |
20-abx652220 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat High Mobility Group Box Protein 3 (HMGB3) Protein |
20-abx652221 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Protein A-Agarose High-Binding 6% Highly Crosslinked |
P9301-005 |
GenDepot |
5ml |
EUR 273.6 |
Protein A-Agarose High-Binding 6% Highly Crosslinked |
P9301-010 |
GenDepot |
10ml |
EUR 416.4 |
Protein A-Agarose High-Binding 6% Highly Crosslinked |
P9301-050 |
GenDepot |
50ml |
EUR 1628.4 |
Protein A-Agarose High-Binding 6% Highly Crosslinked |
P9301-100 |
GenDepot |
100ml |
EUR 2895.6 |